close
close

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results, Provides Business Update

Posted on by Vaseline
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results, Provides Business Update

– Announced Independent Data Monitoring Committee (IDMC) recommendation to continue the Phase 3 REGAL trial in patients with acute myeloid leukemia (AML) without changes: interim analysis expected in Q4 2024 –

– Reported positive preliminary data from the Phase 2a study of SLS009 in r/r AML, demonstrating overall response rates (ORR) to date of 33%, 50%, and 100% at 60 mg QW, 30 mg BIW, and 30 mg BIW with ASXL1 mutation cohorts, respectively –

Related Posts